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LETTER TO THE EDITOR
Is There a Role 
for Whole Brain 
Radiotherapy in 
the Treatment of 
Leptomeningeal 
Metastases?
Morris et al.1 are to be congratu-
lated for their retrospective analysis of 
patients with non–small-cell lung cancer 
(NSCLC) and leptomeningeal metasta-
ses (LM). Several aspects regarding the 
study warrant commentary.
First, this was a single-institution 
retrospective study in which all patients 
with LM (defined by cerebrospinal fluid 
[CSF] cytology or radiographic evidence 
of CSF-disseminated disease) were 
included. Consequently, the study cohort 
was heterogenous with respect to iden-
tified LM prognostic features (the pres-
ence or absence of radiographic bulky 
disease, carcinomatous encephalopathy, 
performance status, and burden of sys-
temic disease), and none were identified 
in the present study. Consequently, it is 
unclear how many patients in the pres-
ent study would be considered as favor-
able risk and considered for LM-directed 
therapy.2,3 Because the present study 
included patients with radiographically 
defined LM, it is unclear how many 
patients in this category (i.e., bulky dis-
ease) were represented.
Because of the retrospective nature 
of the study, there were no a priori deter-
minants of treatment such that treat-
ment was defined individually without 
apparent standardization making cross 
comparisons between treatment groups 
problematic. This feature is perhaps most 
evident in the fact that only 6% of all 
patients were treated with intra-CSF che-
motherapy that may reflect an institutional 
bias with respect to this modality of treat-
ment of LM.4,5 Therefore, Figure 4 in the 
article by Morris et al. 1 is unlikely to be 
reflective of outcome of patients treated 
with intra-CSF chemotherapy because of 
the small number of patients treated and 
the unclear indications for this treatment. 
Admittedly, at present, there has not been 
a randomized study that conclusively 
establishes a role for intra-CSF chemo-
therapy in the treatment of solid-tumor–
related LM.5
Patients receiving whole brain 
irradiation (WBI) were compared with 
patients not treated similarly, and the 
authors suggest no survival advantage 
to treatment of LM with WBI. Given 
that LM is a neuraxis disease with CSF 
dynamically circulating through the intra-
cranial and intraspinal compartments, it 
is not surprising that treatment of only a 
single CSF compartment (the intracra-
nial compartment) with WBI does not 
impact survival. As the authors point 
out, this does not exclude a potential pal-
liative benefit for WBI, a component not 
addressed by the study. Complicating the 
administration of WBI in patients with 
NSCLC and LM is the frequent occur-
rence of parenchymal brain metastases 
that may precede or co-occur with the dis-
covery of LM. Patients previously treated 
with WBI for brain metastases are not 
candidates in general for repeat WBI in 
the event of subsequent discovery of LM.
The statement that there is no appar-
ent survival benefit of WBI in the treatment 
of patients with NSCLC and LM needs to 
be tempered because the indications for 
WBI were not defined, and patients were 
not otherwise comparable with respect to 
prognostic features. Therefore, the util-
ity of WBI in the management of LM is 
still uncertain. As the authors indicate, 
management of solid-tumor–related LM 
remains challenging because of a paucity 
of prospective trials and consequently 
the lack of standardization in LM-related 
treatment that is evidence based.
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New Treatments 
for Leptomeningeal 
Metastases Are 
Urgently Needed
 In Response:
We thank Drs. Chamberlain and 
Eaton for their comments on our recent 
article on leptomeningeal metastasis 
(LM) from non–small-cell lung cancer 
(NSCLC).1,2 As noted, this was a ret-
rospective study of 125 patients diag-
nosed with LM between January 2002 
and December 2009 based on malignant 
cerebrospinal fluid cytologic specimens 
or neuroimaging.1 To the best of our 
knowledge, this is the largest published 
series on LM from NSCLC. Although 
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